CAK1 Antibody

What is CAK1 antigen and where is it expressed?

CAK1 (also designated as CAK1 antigen) is a cell surface antigen approximately 40 kDa in size that is found primarily in human mesothelial tissues and nonmucinous ovarian tumors. Immunohistochemistry studies have demonstrated that CAK1 is expressed uniformly in the mesothelia of peritoneal, pleural, and pericardial cavities. Additionally, the antigen shows significant expression in many ovarian non-mucinous tumors, squamous tumors of the esophagus, and cervical cancer. Limited reactivity has also been observed in normal epithelial tissues of the trachea, tonsil, and Fallopian tube. Unlike some tumor markers, CAK1 appears to be strictly cell-associated and is not detected in the supernatant of cultured cells or in the blood of ovarian cancer patients .

How is CAK1 different from other known antigens like CA125?

While CAK1 shares some tissue reactivity patterns with CA125 (recognized by antibody OC125), several lines of evidence indicate that they are distinct molecular entities. Immunofluorescence competition assays, double-label immunofluorescence experiments, and both solid-phase and live-cell radioimmunoassays have demonstrated that K1 (anti-CAK1) and OC125 (anti-CA125) antibodies recognize different epitopes and likely different molecules. A key distinguishing feature is that unlike CA125, which is shed and can be detected in circulation, CAK1 remains cell-associated and is not found in culture supernatants or patient blood samples. This characteristic makes CAK1 a potential target for localized therapeutic approaches rather than a serum biomarker .

What are the biochemical characteristics of the CAK1 antigen?

The CAK1 antigen displays several notable biochemical properties that have been characterized through various experimental approaches:

• Membrane anchoring: CAK1 is removed from the cell surface by treatment with phosphatidylinositol-phospholipase C, suggesting it is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage.

• Protein structure: CAK1 is sensitive to protease treatment, confirming its protein nature.

• Glycosylation pattern: The antigen is resistant to neuraminidase and beta-galactosidase, indicating absence of certain glycosylation modifications.

• Molecular weight: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analyses of phosphatidylinositol-phospholipase C-released material reveal that CAK1 is approximately a 40 kDa protein.

• Surface retention: The CAK1-K1 antibody complex remains predominantly on the cell surface and exhibits poor internalization .

What is K1 antibody and what is its specificity?

K1 is a monoclonal antibody originally generated by immunizing mice with periodate-treated human ovarian carcinoma (OVCAR-3) cells. The mice were previously made tolerant to normal human kidney membranes to reduce cross-reactivity. The antibody was initially of IgM isotype but was subsequently isotype-switched to IgG1K using panning selection methods. K1 demonstrates high specificity for the CAK1 antigen present on mesothelial cells and various cancer types, particularly nonmucinous ovarian tumors. Immunohistochemistry testing has confirmed its reactivity with ovarian non-mucinous tumors, squamous tumors of the esophagus, and cervical cancer, while showing limited reactivity with normal tissues (primarily mesothelia and limited epithelial tissues). This specificity profile makes K1 a valuable research tool and potential therapeutic targeting agent .

What is the molecular weight of the CAK1 antigen?

The CAK1 antigen has been determined to be approximately 40 kDa in size through SDS-PAGE and immunoblotting analysis. This characterization was performed on material released from cell surfaces by phosphatidylinositol-phospholipase C treatment and detected using a competition radioimmunoassay. The consistent size determination across different experimental approaches confirms that CAK1 is a distinct molecular entity with a well-defined mass, which is important for distinguishing it from other cell surface antigens in research applications .

How can I verify CAK1 presence on cell surfaces in my experimental model?

To verify CAK1 presence on cell surfaces, researchers should employ a multi-modal approach combining:

• Immunofluorescence microscopy: Use K1 antibody with appropriate fluorescent secondary antibodies on living cells (not fixed) to demonstrate surface localization. This should be performed at 4°C to prevent internalization.

• Enzyme sensitivity profiling: Treat cells with:

  • Phosphatidylinositol-phospholipase C (should remove CAK1)

  • Proteases (should remove CAK1)

  • Neuraminidase and beta-galactosidase (should not affect CAK1)
    Then perform immunofluorescence to assess changes in staining patterns.

• Competition radioimmunoassay: To quantify the presence of CAK1 antigen, use radiolabeled K1 antibody and compete with unlabeled antibody or phosphatidylinositol-phospholipase C-released material.

• Immunoblotting: Analyze phosphatidylinositol-phospholipase C-released material via SDS-PAGE and immunoblotting to confirm the 40 kDa band characteristic of CAK1.

Critical controls should include known CAK1-positive cells (e.g., OVCAR-3) and CAK1-negative cells, as well as isotype-matched control antibodies to assess non-specific binding .

What experimental methods can be used to study CAK1-antibody interactions?

Several complementary methodologies can be employed to characterize CAK1-antibody interactions:

• Acid wash immunofluorescence internalization assay: This technique allows assessment of antibody-antigen complex internalization by exposing cells labeled with antibody to acidic conditions that strip surface-bound but not internalized antibody.

• Immunotoxin cytotoxicity assays: Comparing the effects of:

  • K1 conjugated to Lys-PE40 (a mutant Pseudomonas exotoxin lacking cell binding domain)

  • K1 conjugated to native Pseudomonas exotoxin
    These assays can indirectly demonstrate internalization properties, as observed with CAK1-K1 complexes that show poor internalization with K1-Lys-PE40 but cytotoxicity with K1-native exotoxin.

• Radioimmunoassays: Both solid-phase and live-cell radioimmunoassays can be used to quantify binding parameters and evaluate competition between different antibodies.

• Double-label immunofluorescence: This approach allows simultaneous visualization of CAK1 and other antigens, useful for distinguishing between CAK1 and other surface molecules like CA125 .

How do I distinguish between human CAK1 antigen and yeast Cak1 protein kinase in my research?

Distinguishing between human CAK1 antigen and yeast Cak1 protein kinase is critical for research clarity:

When publishing research, clearly specify which CAK1/Cak1 entity is being studied, using either "CAK1 antigen" for the human cell surface protein or "Cak1 kinase" for the yeast protein. If studying both in a comparative context, consider using species prefixes (hCAK1 vs. scCak1) to prevent confusion in the literature .

What controls should be included when using CAK1 antibodies in immunofluorescence studies?

When conducting immunofluorescence studies with CAK1 antibodies, include these essential controls:

• Positive controls:

  • Known CAK1-expressing cell lines (e.g., OVCAR-3)

  • Mesothelial tissue sections

  • Non-mucinous ovarian tumor tissue sections

• Negative controls:

  • Isotype-matched non-specific antibody

  • CAK1-negative cell lines (carefully validated)

  • Mucinous ovarian tumors (should be negative)

• Specificity controls:

  • Pre-treatment of samples with phosphatidylinositol-phospholipase C (should eliminate staining)

  • Pre-incubation of antibody with purified CAK1 antigen (competitive inhibition)

  • Paired staining with OC125 (anti-CA125) to demonstrate distinct patterns

• Technical controls:

  • Secondary antibody only (to assess background)

  • Live vs. fixed cell comparison (CAK1 detection may be compromised by fixation)

  • 4°C vs. 37°C staining (to assess internalization effects)

Document all imaging parameters (exposure times, gain settings) and analyze multiple fields to account for heterogeneity in expression .

How can I assess CAK1 expression in tissue samples?

To comprehensively assess CAK1 expression in tissue samples, implement the following methodological approach:

• Tissue preparation:

  • Use fresh frozen tissue for optimal antigen preservation

  • Alternatively, use carefully fixed tissues with validated fixation protocols

  • Consider both normal and tumor tissues from the same patient when possible

• Immunohistochemistry protocol:

  • Optimize antibody concentration through titration

  • Use avidin-biotin complex method or polymer-based detection for enhanced sensitivity

  • Include appropriate positive controls (mesothelial tissues) and negative controls

• Scoring system:

  • Document both staining intensity (0-3+) and percentage of positive cells

  • Assess membrane vs. cytoplasmic staining separately

  • Evaluate heterogeneity across different regions of the tissue

• Complementary approaches:

  • Confirm with western blotting of tissue lysates when possible

  • Consider in situ hybridization for mRNA expression correlation

  • Compare with other mesothelial markers to confirm cell type

• Analysis considerations:

  • Compare expression between tumor and adjacent normal tissue

  • Document relationship to histological type (particularly for ovarian tumors)

  • Note relationships to mesothelial vs. epithelial morphology

What might cause variations in CAK1 detection across different cell lines?

Variations in CAK1 detection across cell lines can stem from multiple biological and technical factors:

• Biological variations:

  • Differential expression levels related to tissue of origin (mesothelial vs. epithelial)

  • Cell differentiation state (more vs. less differentiated phenotypes)

  • Growth conditions affecting surface protein expression

  • Heterogeneity within cell populations (clonal variations)

• Technical considerations:

  • Surface protein access may be affected by cell density and culture conditions

  • Proteolytic degradation during cell harvesting procedures

  • Variations in GPI-anchor synthesis pathways across cell types

  • Cell fixation protocols may differentially affect epitope accessibility

• Experimental approach solutions:

  • Standardize cell culture conditions (passage number, confluency, media composition)

  • Use multiple detection methods (flow cytometry, immunofluorescence, western blotting)

  • Include quantitative analysis (mean fluorescence intensity measurement)

  • Compare CAK1 detection with other mesothelial markers in parallel

When encountering unexpected variations, consider testing treatment with phosphatidylinositol-phospholipase C to confirm GPI-anchoring as a variable factor in detection efficiency .

How should I interpret unexpected CAK1 localization patterns?

When encountering unexpected CAK1 localization patterns, consider the following interpretation framework:

• Membrane vs. intracellular staining:

  • Normal pattern: Predominantly membrane-associated with minimal internalization

  • Unexpected intracellular staining may indicate:

    • Antibody internalization under experimental conditions (verify with acid wash assay)

    • Cross-reactivity with intracellular proteins (validate with multiple antibodies)

    • Processing/trafficking variations in certain cell types or conditions

• Heterogeneous distribution:

  • Patchy membrane distribution may reflect:

    • Membrane microdomains/lipid raft localization

    • Cell cycle-dependent expression

    • Partial epitope masking by other membrane components

• Validation approaches:

  • Compare live cell vs. fixed cell staining patterns

  • Use membrane fractionation followed by western blotting

  • Employ super-resolution microscopy to resolve submembrane localization

  • Perform double-labeling with membrane domain markers

• Physiological relevance assessment:

  • Determine if localization correlates with functional outcomes

  • Compare with normal mesothelial tissues as reference

  • Evaluate relationship to cellular differentiation state

Remember that the CAK1-K1 antibody complex normally remains on the cell surface with poor internalization, so significant internal staining warrants careful investigation .

What are the potential cross-reactivity concerns with CAK1 antibodies?

Understanding potential cross-reactivity of CAK1 antibodies is essential for experimental validity:

• Known cross-reactivity profiles:

  • K1 antibody shows cross-reactivity between human and cynomolgus monkey tissues

  • Limited reactivity with epithelia of trachea, tonsil, and Fallopian tube

  • Distinguishable from CA125 antigen recognized by OC125 antibody

• Tissue-specific considerations:

  • Mesothelial cells show strongest reactivity

  • Some epithelial tissues show limited reactivity

  • Squamous epithelia (esophagus, cervix) may show significant reactivity

• Mitigation strategies:

  • Pre-absorption with potential cross-reactive tissues

  • Validation with multiple antibody clones when available

  • Correlation with mRNA expression data

  • Competitive inhibition with purified or recombinant antigen

• Experimental validation:

  • Include known negative tissues/cells in each experiment

  • Use isotype-matched control antibodies at equivalent concentrations

  • Perform peptide competition assays when peptide epitopes are known

  • Consider knockout/knockdown validation in appropriate model systems

• Documentation requirements:

  • Clearly report antibody clone, source, and concentration

  • Include all validation steps in publications

  • Provide representative images of both positive and negative controls

How can I verify the specificity of my CAK1 antibody?

To thoroughly verify CAK1 antibody specificity, implement this comprehensive validation strategy:

• Biochemical verification:

  • Western blot analysis should show a single band at approximately 40 kDa

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Enzyme treatments (phosphatidylinositol-phospholipase C, proteases) should eliminate signal

• Cellular verification:

  • Comparative analysis across known positive (mesothelial, OVCAR-3) and negative cell types

  • Flow cytometry analysis for surface expression with appropriate controls

  • Competition assays with purified antigen or peptide epitopes

• Tissue panel evaluation:

  • Test against a comprehensive panel of normal tissues

  • Verify expected staining pattern (mesothelial positivity, limited epithelial reactivity)

  • Compare with published distribution patterns

• Cross-platform concordance:

  • Results should be consistent across multiple detection methods

  • Correlation between protein detection and mRNA expression where data available

  • Reproducibility across different lots of the same antibody

• Functional validation:

  • Antibody-mediated effects should be specific to CAK1-expressing cells

  • Immunotoxin experiments should show selectivity consistent with CAK1 expression

  • Phosphatidylinositol-phospholipase C treatment should abolish antibody binding and functional effects

What factors might affect CAK1 phosphorylation in yeast models?

When studying Cak1 phosphorylation in yeast models, consider these critical influencing factors:

When interpreting phosphorylation data, examine both the mobility shift on polyacrylamide gels (indicating phosphorylation status) and the kinase activity of the target CDKs. Remember that different cak1 alleles show varying severities of phenotypes, with cak1-23 and cak1-34 generally displaying stronger defects than cak1-95 or cak1-22 .

How can CAK1 antibodies be used in ovarian cancer research?

CAK1 antibodies offer several valuable applications in ovarian cancer research:

• Tumor classification and characterization:

  • Differentiating mucinous vs. non-mucinous ovarian tumor subtypes

  • Identifying mesothelial-derived vs. epithelial-derived malignancies

  • Correlation with other biomarkers for improved classification

• Cancer biology investigations:

  • Studying surface antigen expression patterns across ovarian cancer progression

  • Examining the relationship between mesothelial markers and metastatic potential

  • Investigating potential functional roles of CAK1 in cancer cell behavior

• Therapeutic development platforms:

  • Screening models for antibody-drug conjugate development

  • Evaluating CAK1 as a target for immunotherapy approaches

  • Developing targeting strategies for localized treatment delivery

• Translational research applications:

  • Examining patient tissue microarrays for expression correlation with outcomes

  • Assessing CAK1 expression before and after treatment

  • Exploring CAK1 expression in patient-derived xenograft models

• Methodological approaches:

  • Immunohistochemistry on tissue specimens

  • Flow cytometry for cell line characterization

  • In vivo imaging using labeled K1 antibodies to track tumor distribution

K1 antibody specificity for ovarian cancer and mesothelial tissues makes it particularly valuable for distinguishing between primary ovarian tumors and metastases from other sites .

What are the current approaches for using CAK1 antibodies in immunotoxin development?

CAK1 antibodies present unique opportunities and challenges for immunotoxin development:

• Toxin selection considerations:

  • Native Pseudomonas exotoxin is effective despite poor CAK1-K1 internalization, as domain I promotes internalization

  • Lys-PE40 (mutant Pseudomonas exotoxin lacking cell binding domain) is ineffective due to poor internalization

  • This differential response informs toxin selection strategies

• Mechanism optimization:

  • Focus on toxins that can function without requiring extensive internalization

  • Consider membrane-active toxins that can function at the cell surface

  • Explore toxins that require minimal processing to exert cytotoxicity

• Conjugation approaches:

  • Chemical conjugation methods maintaining antibody binding properties

  • Recombinant fusion proteins for standardized production

  • Site-specific conjugation to optimize toxin orientation and function

• Target validation protocols:

  • Confirm differential cytotoxicity between CAK1-positive and negative cells

  • Verify mechanism of action through inhibitor studies

  • Assess potential for resistance development

• Considerations for clinical translation:

  • Evaluation in patient-derived models

  • Assessment of potential off-target effects on normal mesothelial tissues

  • Strategies to minimize immunogenicity of the immunotoxin construct

Understanding the unique cell surface retention properties of the CAK1-K1 complex is critical for successful immunotoxin design, as demonstrated by the selective cytotoxicity observed with K1 conjugated to native Pseudomonas exotoxin but not with K1 conjugated to Lys-PE40 .

How can mutations in CAK1 affect CDK activation pathways?

In yeast models, mutations in CAK1 have revealed intricate effects on CDK activation pathways:

• Differential effects on specific CDKs:

  • Cdc28: All tested cak1 mutations reduce phosphorylation and activity

  • Kin28: Strong alleles (cak1-23, cak1-34) significantly reduce phosphorylation and activity

  • Pho85 and Srb10: Not affected by cak1 mutations

• Mutation-specific impacts:

  • cak1-23 (D226A in α-Helix 4): Most severe effects, mutation in highly conserved residue

  • cak1-34 (G346V in α-Helix 6): Significant effects, mutation in non-conserved residue

  • cak1-95 (G143E in α-Helix 3): Moderate effects, mutation in CDK-conserved residue

  • cak1-22 (EKG313-315 to AA in Loop L14): Milder effects on Kin28

• Genetic interaction patterns:

  • Synthetic effects with cdc28-4: Reduced maximum permissive temperature (35°C to 23°C)

  • Synthetic lethality with kin28-3: Complete inviability at any temperature

  • These genetic interactions confirm functional relationships between these kinases

• Cellular phenotypes observed:

  • Heterogeneous arrest morphology (varies by allele)

  • Defects in cell cycle progression

  • Effects on target protein stability (particularly for Kin28)

• Mechanistic implications:

  • Cak1 directly phosphorylates both Cdc28 and Kin28

  • Different structural elements of Cak1 contribute differentially to substrate specificity

  • Cak1 may have roles beyond simple activating phosphorylation

This detailed understanding provides insight into how CAK1 functions within cellular signaling networks and suggests potential analogous roles in higher eukaryotes, though the specific mechanisms differ significantly between yeast and mammals .

What is the significance of CAK1 in mesothelial tissues versus ovarian tumors?

The distinctive expression pattern of CAK1 in both mesothelial tissues and ovarian tumors has important research and clinical implications:

• Developmental and tissue biology significance:

  • CAK1 expression in normal mesothelia suggests potential roles in mesothelial function

  • Shared expression between mesothelia and ovarian cancers may reflect developmental relationships

  • May provide insight into the cellular origin of certain ovarian tumor subtypes

• Diagnostic applications:

  • Distinguishing primary ovarian tumors from metastases of other origin

  • Differentiating between ovarian tumor subtypes (positive in non-mucinous tumors)

  • Potential marker for mesothelial-derived malignancies

• Biological research opportunities:

  • Investigating common signaling pathways between mesothelial cells and ovarian tumors

  • Exploring the role of mesothelial markers in tumor progression

  • Understanding tissue-specific functions of CAK1

• Therapeutic targeting considerations:

  • Potential for off-target effects on normal mesothelial tissues

  • Opportunity for targeting both primary tumor and peritoneal metastases

  • Developing strategies to enhance tumor specificity

• Comparative expression analysis:

  • CAK1 shows uniform reactivity in mesothelia of peritoneal, pleural and pericardial cavities

  • Non-mucinous ovarian tumors show significant expression

  • Limited expression in certain normal epithelia (trachea, tonsil, Fallopian tube)

This dual expression pattern provides both opportunities and challenges for CAK1-targeted approaches in ovarian cancer research and therapy .

How might CAK1 antibodies be utilized in targeted therapy development?

CAK1 antibodies present several promising avenues for targeted therapy development:

• Antibody-drug conjugate (ADC) approaches:

  • Selection of appropriate toxin payloads considering the limited internalization

  • Optimizing linker chemistry for potential surface action

  • Exploring dual-mechanism ADCs that can function both with and without internalization

• Immune-engaging strategies:

  • Bispecific antibodies linking CAK1-positive cells to immune effectors

  • CAK1-targeted chimeric antigen receptor (CAR) T-cell development

  • Antibody-dependent cellular cytotoxicity (ADCC) enhancement through Fc engineering

• Combination therapy design:

  • CAK1 targeting combined with standard chemotherapy

  • Synergistic approaches with other targeted agents

  • Potential for localized intraperitoneal delivery for ovarian cancer

• Imaging and theranostic applications:

  • Radiolabeled antibodies for tumor detection and monitoring

  • Intraoperative imaging to guide surgical resection

  • Combined diagnostic and therapeutic approaches

• Preclinical validation requirements:

  • Patient-derived xenograft models representing CAK1-positive tumors

  • Assessment of normal tissue toxicity, particularly to mesothelial tissues

  • Careful dose-finding studies to maximize therapeutic window

The persistent surface localization of the CAK1-K1 complex offers unique advantages for certain therapeutic approaches, particularly those not requiring extensive internalization. The selective cytotoxicity observed with native Pseudomonas exotoxin conjugates provides proof-of-concept for the therapeutic potential of appropriately designed CAK1-targeted agents .

What are the key differences between yeast Cak1 and human CAK1?

The nomenclature similarity between yeast Cak1 and human CAK1 can create confusion in research contexts. These entities differ fundamentally in structure, function, and biological context:

While sharing similar names, these proteins represent entirely different molecular entities studied in different experimental contexts. Researchers must clearly distinguish between them in publications to prevent literature confusion .

How should I design experiments to study CAK1 mutations in different systems?

When designing experiments to study CAK1 mutations, different approaches are required depending on whether you're investigating yeast Cak1 or human CAK1:

For yeast Cak1 mutations:

• Generate temperature-sensitive alleles through site-directed mutagenesis targeting:

  • Conserved kinase domains (e.g., D226 in α-Helix 4)

  • CDK-specific conserved residues (e.g., G143 in α-Helix 3)

  • Non-conserved regions (e.g., G346 in α-Helix 6)

• Functional analysis through:

  • Growth phenotype assessment at permissive vs. restrictive temperatures

  • Genetic interaction testing with cdc28 and kin28 mutants

  • Target protein phosphorylation analysis (mobility shifts on gels)

  • Kinase activity assays for Cdc28 and Kin28

• Data analysis approaches:

  • Quantification of growth rates at different temperatures

  • Assessment of cell morphology and cell cycle distributions

  • Correlation of mutation location with phenotype severity

For human CAK1 antigen studies:

• Expression system approaches:

  • Transient or stable expression in appropriate cell lines

  • Site-directed mutagenesis of potential functional domains

  • Analysis of surface localization and antibody binding

• Functional assessments:

  • Antibody binding characteristics (affinity, specificity)

  • GPI-anchor attachment efficiency

  • Surface stability and internalization properties

• Experimental readouts:

  • Flow cytometry for surface expression quantification

  • Immunofluorescence for localization patterns

  • Biochemical analysis of phosphatidylinositol-phospholipase C sensitivity

Clearly distinguish between these systems in all experimental designs and publications to prevent confusion in the literature .

What model systems are most appropriate for CAK1 research?

Selecting appropriate model systems for CAK1 research depends on whether studying yeast Cak1 or human CAK1 antigen:

For yeast Cak1 studies:

• Genetic models:

  • Temperature-sensitive mutants (cak1-23, cak1-34, cak1-95, cak1-22)

  • Strains with epitope-tagged CDK targets (HA-Cdc28, HA-Kin28)

  • Double mutants with cdc28 or kin28 mutations for genetic interaction studies

• Expression systems:

  • Heterologous expression in insect cells for biochemical studies

  • Yeast two-hybrid systems for interaction mapping

  • In vitro reconstitution with purified components

• Key measurements:

  • Growth phenotypes at different temperatures

  • Cell cycle progression analysis

  • Target protein phosphorylation status

  • Kinase activity assays

For human CAK1 antigen research:

• Cell line models:

  • OVCAR-3 (high CAK1 expression)

  • Primary mesothelial cell cultures

  • Cell panels representing different ovarian cancer subtypes

• Tissue models:

  • Patient-derived xenografts of CAK1-positive tumors

  • Tissue microarrays of ovarian cancers and mesothelial tissues

  • Fresh tissue explant cultures

• Animal models:

  • Mouse xenograft models with human CAK1-positive tumor cells

  • Models for antibody biodistribution and targeting studies

  • Imaging studies using labeled K1 antibody

• Key measurements:

  • Immunohistochemistry for expression patterns

  • Flow cytometry for quantitative surface expression

  • Antibody binding and internalization kinetics

  • Therapeutic response to CAK1-targeted agents

Carefully document and report the specific model system used and its relevance to the particular CAK1 entity under investigation .